A
Anne Ryan
Researcher at National Institutes of Health
Publications - 3
Citations - 2519
Anne Ryan is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Prostate cancer & Prostate Cancer Prevention Trial. The author has an hindex of 3, co-authored 3 publications receiving 2464 citations.
Papers
More filters
Journal ArticleDOI
The Influence of Finasteride on the Development of Prostate Cancer
Ian M. Thompson,Phyllis J. Goodman,Catherine M. Tangen,M. Scott Lucia,Gary J. Miller,Leslie G. Ford,Michael M. Lieber,R. Duane Cespedes,JN Atkins,Scott M. Lippman,Susie M. Carlin,Anne Ryan,Connie M. Szczepanek,John Crowley,Charles A. Coltman +14 more
TL;DR: Finasteride prevents or delays the appearance of prostate cancer, but this possible benefit and a reduced risk of urinary problems must be weighed against sexual side effects and the increased risk of high-grade prostate cancer.
Journal ArticleDOI
Delivering prostate cancer prevention messages to the public: how the National Cancer Institute (NCI) effectively spread the word about the Prostate Cancer Prevention Trial (PCPT) results.
TL;DR: The groundbreaking yet complicated results of the Prostate Cancer Prevention Trial were widely disseminated by National Cancer Institute using the social marketing and public-relations strategies and tactics detailed here.
Journal ArticleDOI
Factors Associated with Adherence to an End-of-Study Biopsy: Lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S9217)
Ellen R. Gritz,Kathryn B. Arnold,Carol M. Moinpour,Allison M. Burton-Chase,Catherine M. Tangen,Jeffrey F. Probstfield,William A. See,Michael M. Lieber,Vincent Caggiano,Sarah Moody-Thomas,Connie M. Szczepanek,Anne Ryan,Susie M. Carlin,Shannon Hill,Phyllis J. Goodman,Rose Mary Padberg,Lori M. Minasian,Frank L. Meyskens,Ian M. Thompson +18 more
TL;DR: Good adherence to study requirements 1 year before the EOS biopsy was associated with greater odds that a participant would comply with the invasive EOS requirement, which may identify participants at risk of nonadherence to more demanding study end points.